Hormone receptor positive breast cancer+1
Not recruitingStudy of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer
Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer
- Disease:Hormone receptor positive breast cancerHER2 positive breast cancer
- Substances:–
Belgium- Participants:18–64 years · 65+ years
- Sponsor:F. Hoffmann-La Roche AG












